`Petitioner’s Motion to Seal
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________________
`
`Altaire Pharmaceuticals, Inc.,
`Petitioner,
`
`v.
`
`Paragon BioTeck, Inc.,
`Patent Owner.
`
`____________________
`
`U.S. Patent No. 8,859,623
`CASE: PGR2015-00011
`____________________
`
`
`
`
`
`
`
`
`
`PETITIONER’S MOTION TO SEAL
`
`
`
`U.S. Patent No. 8,859,623
`Petitioner’s Motion to Seal
`
`I.
`
`
`STATEMENT OF RELIEF REQUESTED
`
`Pursuant to 37 C.F.R. § 42.14 and the previously submitted Protective
`
`Order (Exh. 2012), Altaire Pharmaceuticals, Inc. (“Petitioner”) respectfully moves
`
`to seal portions of its Reply (“Petitioner’s Reply”), portions of Exhibit 1029, and
`
`Exhibits 1027, 1028, and 1030 (see Table 2 below). As detailed below,
`
`Petitioner’s Reply and the Exhibits contain information that (a) Paragon BioTeck,
`
`Inc. (“Paragon” or “Patent Owner”) considers highly confidential, and (b) Altaire
`
`considers highly confidential and extremely sensitive and does not wish to be made
`
`publicly available.
`
`II.
`
`
`
`PARAGON ALLEGES GOOD CAUSE EXISTS FOR SEALING
`INFORMATION
`
`Petitioner seeks to seal portions of its Reply that Patent Owner considers
`
`highly confidential. As asserted in its Motion to Seal filed August 24, 2015,
`
`Paragon asserts this information is not publicly available, and that disclosure of
`
`this information would significantly harm Paragon. See Patent Owner’s Motion to
`
`Seal and Motion for entry of Protective Order Pursuant to 37. C.F.R. § 42.14 and §
`
`42.54, PGR2015-00011, Paper 6, 2 (P.T.A.B. 2015).1
`
`
`1 Contrary to Patent Owner’s representations, Petitioner does not agree that the
`
`information is highly confidential; however, as a courtesy, Petitioner has not
`
`opposed Patent Owner’s motions to seal the information.
`
`1
`
`
`
`
`
`U.S. Patent No. 8,859,623
`Petitioner’s Motion to Seal
`
`
`
`As such, Petitioner has redacted only the specific information relating to
`
`the Agreement that Paragon has previously redacted from Exhibit 2004. See Table
`
`1 infra.
`
`TABLE 1
`
`Paper No.
`
`Title
`
`Portions with Redacted
`
`Information
`
`Paper No.
`
`Petitioner’s Reply
`
`p. 21, ll. 8-9
`
`p. 23, l. 10
`
`p. 25, ll. 2-3
`
`
`
`III. GOOD CAUSE EXISTS FOR SEALING PETITIONER’S
`INFORMATION
`
`
`
`Petitioner seeks to file portions of Exhibits 1027-1030 under seal. The
`
`information Petitioner seeks to seal reflects proprietary and confidential testing
`
`methodologies developed by Petitioner. See Ex. 1003 at ¶ 21. Petitioner’s
`
`patentability arguments relate to the results generated, and previously publicly
`
`disclosed, by these testing methodologies, and are included in reply to Patent
`
`Owner’s arguments.
`
`2
`
`
`
`
`
`U.S. Patent No. 8,859,623
`Petitioner’s Motion to Seal
`
`
`
`Petitioner’s testing methods have not been published or otherwise made
`
`public. Petitioner, instead, has taken efforts to maintain the confidentiality of this
`
`information. For example, Exhibits 1027 and 1030 are marked: “This document
`
`contains information that is privileged, confidential and is protected from
`
`disclosure under applicable law. This document is the sole property of Altaire
`
`Pharmaceuticals, Inc.” See Ex. 1027; Ex. 1030. Exhibit 1028 similarly recites the
`
`same information as Exhibit 1027, and Petitioner has treated Exhibit 1028 as
`
`confidential and efforts have been made to ensure it does not become publicly
`
`available. See, e.g., Ex. 1003 at ¶ 21.
`
`
`
`Similarly, Petitioner redacted only specific information from Exhibit
`
`1029 that it considers confidential information relating to its proprietary and
`
`confidential testing methodologies discussed above. As such, Petitioner has
`
`narrowly redacted the testimony.
`
`
`
`Disclosure of the information could significantly harm at least
`
`Petitioner’s competitiveness in the market. As Petitioner has previously asserted,
`
`the information disclosed in Exhibits 1027-1030 reflect proprietary testing
`
`methodologies capable of distinguishing R and S phenylephrine hydrochloride.
`
`The disclosure of Petitioner’s proprietary information would allow competitors to
`
`3
`
`
`
`
`
`U.S. Patent No. 8,859,623
`Petitioner’s Motion to Seal
`
`successfully employ Petitioner’s methodologies without incurring the costs
`
`associated with the research and development of those methodologies.
`
`
`
`“The rules aim to strike a balance between the public’s interest in
`
`maintaining a complete and understandable file history and the parties’ interest in
`
`protecting truly sensitive information.” Office Patent Trial Practice Guide, 77
`
`Fed. Reg. 48756, 48760 (Aug. 14, 2012). The balance in this proceeding shifts
`
`toward maintaining the confidentiality of Petitioner’s testing methodologies. First,
`
`Petitioner has previously maintained the information as confidential and
`
`proprietary. Furthermore, there is little if any public interest in the details of
`
`Petitioner’s testing methodologies – the public’s interest remains in the results
`
`from those testing methodologies, which were previously publicly filed. Finally,
`
`the detailed information Petitioner seeks to seal is also not required by the Board to
`
`make any determination in this proceeding. Accordingly, the public interest will
`
`not be harmed by filing the information under seal.
`
`TABLE 2
`
`Paper No. / Exhibit No.
`
`Title
`
`Portions with Redacted
`
`Information
`
`4
`
`
`
`
`
`U.S. Patent No. 8,859,623
`Petitioner’s Motion to Seal
`
`Exhibit 1027
`
`TMQC-247-01
`
`Entire Document
`
`Exhibit 1028
`
`TMQC-247-00
`
`Entire Document
`
`Exhibit 1029
`
`Zaman Declaration
`
`p. 4, ll. 11-13
`
`p. 5, ll. 10-15
`
`p. 7, ll. 7-16
`
`Exhibit 1030
`
`STU0346
`
`Entire Document
`
`
`
`
`
`
`
`Dated: May 6, 2016
`
`Respectfully submitted,
`
` /Dipu A. Doshi/
`By: ____________________
`Dipu A. Doshi.
` Registration No.: 60,073
`BLANK ROME LLP
`1825 Eye Street, NW
`Washington, DC 20006-5403
`(202) 420-2200
`Attorneys for Petitioner
`
`5
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`U.S. Patent No. 8,859,623
`Petitioner’s Motion to Seal
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that a copy of the foregoing PETITIONER’S
`
`MOTION TO SEAL is being served on counsel of record by filing this document
`
`via electronic mail.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/Dipu A. Doshi/
`
`Dipu A. Doshi
`
`Registration No. 60,073
`
`BLANK ROME LLP
`
`1825 Eye Street NW
`
`Washington DC 20006
`
`Tel: 202-420-4742
`
`Counsel for Petitioner
`
`6
`
`
`
`
`Dated: May 6, 2016